ArticleBiomaterials research2026
Visible-Light-Curable Catechol-Reinforced Gelatin Bioglue for Rapid Hemostasis and Engineered Tissue Assembly.
Article in Biomaterials research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hydrogel-based tissue adhesives hold promise for diverse biomedical applications, yet achieving strong, durable adhesion to wet, dynamic biological surfaces remains challenging. The catechol-containing amino acid 3,4-dihydroxy-l-phenylalanine (DOPA) is a crucial functional motif in mussel-inspired adhesives and has been extensively investigated for incorporation into various biomaterials. However, conventional approaches of DOPA incorporation and subsequent crosslinking have shown limited potential for clinical translation. We developed a bioinspired strategy involving pH-controlled enzymatic conversion of tyrosine residues in porcine gelatin into DOPA. The resulting catechol-functionalized gelatin was blended with native tyrosine-rich gelatin to form a hybrid adhesive hydrogel, termed DOPA-tyrosine gelatin (DTG) bioglue. DTG was designed to achieve (a) rapid visible-light-driven ruthenium-based crosslinking for structural integrity and (b) enhanced interfacial adhesion via DOPA-mediated interactions with tissue surface. Its shear-thinning and fast-curing properties enable its use as a bioink for both extrusion-based and digital-light-processing 3-dimensional bioprinting. We demonstrated the DTG-assisted tissue-tissue integration for large-area construct assembly, addressing current volumetric fabrication limitations in microextrusion bioprinting. Moreover, it demonstrated superior hemostatic performance in rat liver and vascular injury models. Collectively, DTG bioglue is a promising candidate for next-generation adhesive biomaterial for regenerative medicine and surgical applications.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.